Indoco Remedies Q2 net loss narrows to <span class='rupeeNews'>R<span>s</span></span> 9 cr

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

16 January 2026 00:00:00

Adani Ports

1421.50

(-0.57%)

Asian Paints

2756.90

(-2.08%)

Axis Bank

1294.55

(-0.30%)

Bajaj Finance

950.50

(0.47%)

Bajaj Finserv

2002.40

(0.04%)

Bharat Electro..

410.15

(-1.85%)

Bharti Airtel

2016.00

(-0.35%)

Eternal

287.55

(-3.89%)

HCL Technologi..

1698.90

(1.82%)

HDFC Bank

931.15

(0.56%)

Hind. Unilever

2359.65

(0.26%)

ICICI Bank

1411.65

(-0.46%)

Infosys

1689.40

(5.65%)

Interglobe Avi..

4738.70

(0.13%)

ITC

329.25

(-1.64%)

Kotak Mah. Ban..

418.25

(-0.65%)

Larsen & Toubr..

3855.90

(-0.25%)

M & M

3658.75

(0.26%)

Maruti Suzuki

15856.55

(-1.78%)

NTPC

346.25

(-0.83%)

Power Grid Cor..

257.25

(-0.41%)

Reliance Indus..

1457.60

(-0.06%)

SBI

1042.30

(1.36%)

Sun Pharma.Ind..

1669.20

(-1.84%)

Tata Steel

188.10

(-0.61%)

TCS

3206.70

(0.45%)

Tech Mahindra

1670.55

(5.17%)

Titan Company

4196.90

(-0.57%)

Trent

3901.75

(-0.73%)

UltraTech Cem.

12372.55

(0.94%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Indoco Remedies Q2 net loss narrows to Rs 9 cr	Share Back
(06 Nov 2025)
Revenue from operations stood at Rs 471.83 crore in the second quarter of FY26, up 9.59% as against Rs 430.66 crore posted in Q2 FY25. The company reported a pre-tax loss of Rs 13.35 crore in Q2 FY26, compared with a pre-tax loss of Rs 4.84 crore in Q2 FY25. The firm also recorded exceptional items amounting to Rs 0.53 crore during the quarter. EBITDA for the quarter stood at Rs 53.4 crore, compared with Rs 52.9 crore in the corresponding quarter of the previous year. Aditi Panandikar, MD, Indoco Remedies, said, “International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters. Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization. Shares of Indoco Remedies fell 1.72% to currently trade at Rs 268.50 on the BSE.
Top